NRC Nrc Health
Updated
Industrials · Services-Commercial Physical & Biological Research
Nrc Health (NRC) is a industrials company in the Services-Commercial Physical & Biological Research industry, with a market capitalization of $470 million. Shares last traded at $21.25, 15.0% below their 52-week high. Over the past year the stock is up 44.2%. NRC trades at a price-to-earnings ratio of 40.51, above the Services-Commercial Physical & Biological Research median of 33.22. Net profit margin is 8.3%, in line with the peer median of 8.3%. Revenue declined 4.0% year over year. The shares yield 2.6% in dividends.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
NRC Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $11M | $0.49 | 95% |
| 2024-12-31 | $11M | $0.48 | 46% |
| 2023-12-31 | $36M | $1.47 | 117% |
| 2022-12-31 | $21M | $0.84 | 66% |
| 2021-12-31 | $9M | $0.36 | 24% |
| 2020-12-31 | $11M | $0.41 | — |
| 2019-12-31 | $31M | $1.22 | — |
| 2018-12-31 | $17M | — | 56% |
| 2017-12-31 | $17M | — | 74% |
| 2016-12-31 | $29M | — | 139% |
| 2015-12-31 | $10M | — | 57% |
| 2013-12-31 | $2M | — | 14% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-0.01 | 2026-08-04 |
| Q1 2026 | $0.14 | 2026-05-06 |
| FY 2025 | $50.00 | 2026-03-05 |
| Q3 2025 | $0.43 | 2025-11-07 |
| Q2 2026 | $0.25 | 2026-08-04 |
| Q1 2026 | $0.25 | 2026-05-06 |
Services-Commercial Physical & Biological Research peers
NRC vs 14 industry peers (Services-Commercial Physical & Biological Research), by market cap. Updated
| IQV | IQVIA | $45.3B | 32.74 | 2.73 | 8.3% | +2.95% |
| INCY | Incyte | $25.6B | 17.86 | 4.77 | 26.7% | -0.68% |
| MEDP | Medpace Holdings, Inc. | $16.6B | 33.70 | 5.95 | 17.7% | +0.09% |
| CRL | Charles River Laboratories | $14.0B | -58.72 | 3.50 | -6.0% | +0.54% |
| ABSI | Absci Corp | $1.5B | -12.46 | 332.71 | — | -0.06% |
| OABI | OmniAb, Inc. | $689M | -15.57 | — | — | -5.77% |
| NRC | Nrc Health | $470M | 40.51 | 3.36 | 8.3% | +6.23% |
| MXCT | MAXCYTE, INC. | $131M | -3.66 | — | — | -1.17% |
| BIAF | bioAffinity Technologies, Inc. | $100M | -6.60 | — | — | +22.48% |
| ONMD | OneMedNet Corp | $35M | -4.15 | — | — | +4.13% |
| ISPC | iSpecimen Inc. | $4M | -0.34 | — | — | +4.70% |
| IBACR | IB Acquisition Corp. | $580955 | -1.45 | — | — | +0.87% |
| ICLR | Icon Plc | — | — | — | 2.1% | +2.36% |
| BIAFW | bioAffinity Technologies, Inc. | — | — | — | — | +80.18% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.